258 related articles for article (PubMed ID: 25525394)
41. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
42. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
43. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.
Huang Y; He Q; Xu K; Zhou J; Yin J; Li F; Feng M; Lang J
Int J Gynecol Cancer; 2019 Mar; 29(3):459-465. PubMed ID: 30733276
[TBL] [Abstract][Full Text] [Related]
44. A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients.
Coronel JA; Cetina Ldel C; Cantú D; Cerezo O; Hernández CS; Rivera L; Chacón AP; Duenas-Gonzalez A
Int J Gynecol Cancer; 2013 Jun; 23(5):884-9. PubMed ID: 23694982
[TBL] [Abstract][Full Text] [Related]
45. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
[TBL] [Abstract][Full Text] [Related]
46. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
47. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
48. [VEGF--targeted therapy for the treatment of cervical cancer --literature review].
Salomon-Perzyńska M; Perzyński A; Rembielak-Stawecka B; Michalski B; Skrzypulec-Plinta V
Ginekol Pol; 2014 Jun; 85(6):461-5. PubMed ID: 25029813
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
50. Advances in immunotherapy for cervical cancer.
Grau-Bejar JF; Garcia-Duran C; Garcia-Illescas D; Mirallas O; Oaknin A
Ther Adv Med Oncol; 2023; 15():17588359231163836. PubMed ID: 37007635
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
52. Chemoradiotherapy for cervical cancer.
Rose PG
Eur J Cancer; 2002 Jan; 38(2):270-8. PubMed ID: 11803143
[TBL] [Abstract][Full Text] [Related]
53. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
54. [Molecular basis of cervical carcinogenesis by high-risk human papillomaviruses].
Yugawa T; Kiyono T
Uirusu; 2008 Dec; 58(2):141-54. PubMed ID: 19374192
[TBL] [Abstract][Full Text] [Related]
55. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
56. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
57. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis.
Lukka H; Hirte H; Fyles A; Thomas G; Elit L; Johnston M; Fung MF; Browman G;
Clin Oncol (R Coll Radiol); 2002 Jun; 14(3):203-12. PubMed ID: 12109823
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
Gupta S; Maheshwari A; Parab P; Mahantshetty U; Hawaldar R; Sastri Chopra S; Kerkar R; Engineer R; Tongaonkar H; Ghosh J; Gulia S; Kumar N; Shylasree TS; Gawade R; Kembhavi Y; Gaikar M; Menon S; Thakur M; Shrivastava S; Badwe R
J Clin Oncol; 2018 Jun; 36(16):1548-1555. PubMed ID: 29432076
[TBL] [Abstract][Full Text] [Related]
59. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results.
Cetina L; Rivera L; Hinojosa J; Poitevin A; Uribe J; López-Graniel C; Cantú D; Candelaria M; de la Garza J; Dueñas-González A
BMC Womens Health; 2006 Feb; 6():3. PubMed ID: 16464243
[TBL] [Abstract][Full Text] [Related]
60. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
